Physician profile
George Cameron Coleman
NPI 1801241104
$437.21
in general payments reported to CMS, 2019-2025
11 companies · $409 in 2025
The $409 reported for 2025 was more than what 84% of Addiction Medicine (Preventive Medicine) providers received nationally (typical 2025 total: $115).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $28.57 · 2025: $409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $409.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $408.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $82.08 | 2025 | Caplyta |
| Indivior INC. | $74.53 | 2025 | Sublocade |
| Vanda Pharmaceuticals INC. | $66.46 | 2025 | Hetlioz, Fanapt |
| Axsome Therapeutics, INC. | $44.92 | 2025 | Auvelity |
| Lundbeck LLC | $34.36 | 2025 | Rexulti |
| Novo Nordisk INC | $28.57 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $24.43 | 2025 | Uzedy |
| Janssen Pharmaceuticals, INC | $22.51 | 2025 | Spravato |
| Braeburn INC. | $21.67 | 2025 | Brixadi |
| Alkermes, INC. | $19.65 | 2025 | Aristada, Lybalvi |
| Bausch Health US, LLC | $18.03 | 2025 | Aplenzin, Wellbutrin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Coleman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.